Browsing by Author Ross, David M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2017Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyureaStevenson, William; Bennett, Michael; Douglas, Genevieve; Forsyth, Cecily; Grigg, Andrew; Harrison, Claire; Hounsell, John; Ratnasingam, Sumita; Ritchie, D; Ross, David M; Northern Clinical School: MedicineBusulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea, Leukemia and Lymphoma, vol.58, 1, 2017,pp 89-95
2017A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosisHo, Joy Phoebe; Bajel, A; Burbury, Kate; Dunlop, L; Durrant, S; Forsyth, Cecily; Perkins, A; Ross, David M; Central Clinical School: MedicineA case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis, Internal Medicine Journal, vol.47, 3, 2017,pp 262-268
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLHertzberg, Mark; Altamura, Haley K; Branford, Susan; et al, Various; Field, Chani R; Georgievski, Jasmina; Jamison, Bronte A; Phillis, Stuart; Prime, Jodi A; Ross, David M; Yeoman, Alexandra L; Yeung, David; Western Clinical School: Medicine (Westmead)Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML, Blood, vol.121, 19, 2013,pp 3818-3824
2015Practical management of myelofibrosis with ruxolitinibHo, Joy Phoebe; Stevenson, William; Bird, Robert; Dunlop, L; Durrant, S; Marlton, Paula V; Ritchie, D; Ross, David M; Tam, Constantine; Central Clinical School: Medicine; Northern Clinical School: MedicinePractical management of myelofibrosis with ruxolitinib, Internal Medicine Journal, vol.45, 12, 2015,pp 1221-1230